Aadi Bioscience Inc (OQ:AADI)

Business Focus: Biopharmaceuticals

Get the company report for the most recent outlook updated daily

May 08, 2024 08:00 am ET

Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update

Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024

May 01, 2024 08:00 am ET

Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update

Company to Host Conference Call and Webcast on May 8, 2024

Apr 09, 2024 08:00 am ET

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a Phase 2 trial

Feb 26, 2024 03:05 pm ET

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference

LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston. Dave Lennon, Ph.D., President and CEO, will present a company overview on Monday, March 4, 2024, from 2:10 PM – 2:40 PM ET.

Jan 26, 2024 03:05 pm ET

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations

Jan 19, 2024 03:05 pm ET

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

- New real-world analysis highlights unmet medical need in GI cancer patients with TSC1/2 alterations-

Dec 14, 2023 03:05 pm ET

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population

Nov 08, 2023 07:00 am ET

Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update

PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of early interim analysis by mid-December 2023; multiple 2024 catalysts expected

Nov 06, 2023 03:05 pm ET

Aadi Bioscience to Participate in Jefferies London Healthcare Conference

LOS ANGELES, Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London. Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Tuesday, November 14, 2023, at 8:30 am GMT.

Nov 01, 2023 04:05 pm ET

Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update

Company to Host Conference Call and Webcast on Wednesday, November 8, 2023

Oct 19, 2023 04:05 pm ET

Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting

Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer (EEC)

Oct 12, 2023 04:05 pm ET

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population

Oct 05, 2023 04:05 pm ET

Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium

LOS ANGELES, Oct. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that two posters will be presented at the upcoming North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, taking place October 4-6, 2023, in Montreal, Canada.

Oct 03, 2023 04:05 pm ET

Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

LOS ANGELES, Oct. 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that an equity award has been granted to its new President and Chief Executive Officer, Dave Lennon, Ph.D., on October 2, 2023, the first date of his employment (the "Grant Date"), in accordance with the Aadi Bioscience, Inc. 2023 Inducement Plan (the "Plan"). The award was granted pursuant to the terms of Dr. Lennon's employment agreement and as a material induceme

Oct 02, 2023 08:00 am ET

Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors

Sep 20, 2023 04:30 pm ET

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

LOS ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.

Aug 02, 2023 08:00 am ET

Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update

Company to Host Conference Call and Webcast on Wednesday, August 9, 2023

May 25, 2023 05:30 pm ET

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES, May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced poster presentations at the 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL. The abstracts associated with the poster presentations are now available on the ASCO meeting website.

May 23, 2023 08:00 am ET

Aadi Bioscience to Participate in Upcoming Investor Events

LOS ANGELES, May 23, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation at the following investor events:

May 10, 2023 08:00 am ET

Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial

Total 1Q 2023 revenue on FYARRO® sales of $5.9 million

May 03, 2023 08:00 am ET

Aadi Bioscience to Report First Quarter 2023 Results and Operational Update

Company to Host Conference Call and Webcast on Wednesday, May 10, 2023

Apr 26, 2023 04:05 pm ET

Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.

Apr 14, 2023 01:00 pm ET

Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.

Apr 06, 2023 04:30 pm ET

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023

LOS ANGELES, April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL.

Mar 28, 2023 08:00 am ET

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update

Total revenue on FYARRO® sales of $15.2 million for FY 2022

Mar 27, 2023 08:00 am ET

Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors

LOS ANGELES, March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors. Dr. Hirmand has more than 20 years of biotechnology clinical development experience, and recently served as executive vice president and chief medical officer for Turning Point Therapeutics, which was acquired by Bristol Myers Squibb (BMS) for $4.1 bi

Mar 26, 2023 02:00 pm ET

Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer

LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.

Mar 15, 2023 08:00 am ET

Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update

Company to Host Conference Call and Webcast on March 28, 2023

Nov 17, 2022 07:00 am ET

Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

Trial-in-progress poster showcases clinical trial design for PRECISION 1 and two additional posters demonstrate favorable durability of response and long-term safety of nab-sirolimus in the completed AMPECT study

Nov 09, 2022 07:00 am ET

Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update

Completed $72.5 million PIPE financing extending cash runway into 2025

Nov 08, 2022 03:00 pm ET

Aadi Bioscience Announces Planned Leadership Transition

LOS ANGELES, Nov. 8, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Neil Desai, Founder, President and CEO to Executive Chairman and Brendan Delaney, Chief Operating Officer, to President and CEO, effective as of January 1, 2023.

Nov 03, 2022 08:00 am ET

Aadi Bioscience to Present at Upcoming Investor Conferences

LOS ANGELES, Nov. 3, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences during November:

Nov 02, 2022 08:00 am ET

Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update

Company to Host Conference Call and Webcast on November 9

Oct 27, 2022 08:00 am ET

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium

Nab-sirolimus added to KRAS inhibitor treatment demonstrated significantly greater antitumor activity and tumor regressions compared to the KRAS inhibitors alone

Oct 12, 2022 08:01 am ET

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium

Poster presentation scheduled for October 27, 2022

Oct 12, 2022 08:00 am ET

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C

SAN DIEGO and LOS ANGELES, Oct. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung

Sep 22, 2022 04:01 pm ET

Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing

LOS ANGELES, Sept. 22, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock ("Common Stock") at a price of $12.50 per share, reflecting the closing price on September 21, 2022 on NASDAQ, and pre-funded warrants ("Pre-Funded Warrants") to purch

Sep 01, 2022 08:00 am ET

Aadi Bioscience Announces Participation in Upcoming September Investor Conferences

LOS ANGELES, Sept. 1, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be participating in and hosting one-on-one meetings at the following conferences during September:

Aug 10, 2022 08:00 am ET

Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update

FYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022

Jul 28, 2022 08:30 am ET

Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update

Company to Host Conference Call and Webcast on August 10

Jun 23, 2022 08:00 am ET

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small...

Jun 01, 2022 08:00 am ET

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference

May 31, 2022 08:00 am ET

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

May 26, 2022 05:10 pm ET

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting

May 18, 2022 07:00 am ET

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference

Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive...

May 12, 2022 08:32 am ET

UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced financial results for the first...

May 12, 2022 07:00 am ET

Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 09, 2022 08:00 am ET

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

May 04, 2022 08:00 am ET

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

Apr 28, 2022 05:07 pm ET

Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

Apr 18, 2022 08:00 am ET

Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit

Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief...

Apr 08, 2022 01:09 pm ET

Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)

Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of a...

Mar 31, 2022 02:45 pm ET

Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and T

Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the commencement of dosing in PRECISION 1, a Phase 2...

Mar 17, 2022 07:00 am ET

Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Mar 01, 2022 07:00 am ET

Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference

Aadi Bioscience, Inc. (“Aadi”) (Nasdaq:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President,...

Feb 23, 2022 07:00 am ET

Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the launch and commercial availability of its first...

Jan 04, 2022 04:30 pm ET

Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai,...

Nov 23, 2021 08:45 am ET

Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Grey, Aadi Bioscience, or Emergent Biosolutions?

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO, NVTS, BGRY, AADI, and EBS.

Nov 23, 2021 06:00 am ET

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the U.S. Food and Drug Administration (FDA) has...

Nov 15, 2021 08:00 am ET

UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced two oral presentations that were made...

Nov 13, 2021 01:35 pm ET

Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

Nov 10, 2021 07:00 am ET

Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 09, 2021 08:00 am ET

Aadi Bioscience to Participate in Upcoming Investor Conferences

Aadi Bioscience, Inc. (“Aadi”), clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that management will be participating in the upcoming...

Nov 01, 2021 04:05 pm ET

Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer

Oct 25, 2021 08:00 am ET

Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer

Oct 22, 2021 08:00 am ET

Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology

Oct 19, 2021 05:22 pm ET

Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021

Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer...

Oct 06, 2021 08:00 am ET

Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Sep 20, 2021 08:30 am ET

Ad blocking detected

Aadi Bioscience Inc (OQ:AADI)

Business Focus: Biopharmaceuticals